Time Magazine
•84% Informative
SER-109 is the first oral drug designed to treat the microbiome.
It's a cocktail of bacteria that can prevent recurring infections of C. difficil Apr. 26 ri the U.S. Food and Drug Administration so FDA .
About 156,000 infections occur in the U.S. each year, causing diarrhea, cramping, dehydration and first r.
If SER-109 and SER-155 show benefit in adjusting the gut microbiome, then other infections might also join the list.
“This approval is the tipping point for the field,” says Shaff. “We have the opportunity to treat patients with C. difficile infections, but that is by no means the end of the story.”. TIME FDA eed_highLightText__NxlGi">Four Seres Therapeutics xlGi">the Movie Star From Extincti Nestle Health Science s="s nearly 200 _highLightText__NxlGi">Democra C. C. Shaff the U.S. Centers for Disease Control and Prevention hL CDC tTe about one ">C. six pan> C. yFeed_highLightText__NxlGi">Shaffone
VR Score
86
Informative language
85
Neutral language
58
Article tone
formal
Language
English
Language complexity
58
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links